Comparative Pharmacology
Head-to-head clinical analysis: M V I PEDIATRIC versus MULTIFUGE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M V I PEDIATRIC versus MULTIFUGE.
M.V.I. PEDIATRIC vs MULTIFUGE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multivitamin preparation providing essential vitamins (A, C, D, E, K, B1, B2, B3, B5, B6, B7, B9, B12) as cofactors for enzymatic reactions, antioxidant functions, and maintenance of normal metabolic processes.
Multifuge is a combination product containing an antihistamine and a decongestant. The antihistamine (chlorpheniramine) competitively antagonizes histamine H1 receptors, reducing allergic symptoms. The decongestant (pseudoephedrine) stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
Intravenous infusion: 5 mL (1 vial) added to appropriate IV fluid, administered over 30 minutes daily.
IV: 10 mg/kg body weight as a single dose; repeated every 48 hours as needed.
None Documented
None Documented
Variable; vitamin A: 9-25 days (stored in liver), vitamin D: 2-3 weeks (fat-soluble), vitamin C: 10-20 hours (renal function dependent), B-complex: 1-10 hours. Clinical context: accumulation risk in renal impairment.
The terminal elimination half-life is 7-9 hours in adults with normal renal function. This may be prolonged (up to 20-30 hours) in patients with severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Renal: 60-80% (free vitamins), Biliary/fecal: 10-20% (unabsorbed and metabolites).
Renal excretion of unchanged drug accounts for 60-70% of the administered dose, with the remainder undergoing hepatic metabolism to inactive metabolites that are excreted renally. Fecal elimination is minimal (<5%).
Category C
Category C
Multivitamin
Multivitamin/Mineral Supplement